ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VERA vs AUPH // NET PROFIT MARGIN

Vera Therapeutics Inc. (Class A) (NASDAQ) VS. Aurinia Pharmaceuticals Inc (NASDAQ) • 15-METRIC TALLY: VERA 2 — AUPH 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VERA VS. AUPH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VERA AUPH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 88.50% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 16.50% -51.50 AUPH /roic <GO>
EV/EBITDA & P/E Valuation — 21.1x — TIE /valuation <GO>
Free Cash Flow Yield -10.99% 5.92% -16.91 AUPH /fcf-yield <GO>
Operating Margin — 37.10% — TIE /operating-margins <GO>
Net Profit Margin ACTIVE — 68.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 20.40% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 8.33 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 7/9 -5.00 AUPH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.7 49.1 +3.60 VERA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 6.7x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.23B $2.22B $17.2M VERA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VERA REV AUPH REV VERA GROSS % AUPH GROSS % VERA FCF AUPH FCF
FY 2025 $883.3M $283.1M — 88.5% -$241.7M $135.7M
FY 2024 $468.1M $235.1M — 88.0% -$135.7M $44.4M
FY 2023 $285.6M $175.5M — — -$92.2M -$33.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VERA // BETA —
AUPH // BETA —